Group 1 - The core issue raised by the proposed executive order from President Trump is the potential impact on pharmaceutical companies' investments in the U.S., particularly Roche's planned $50 billion investment [1][3] - Roche expressed concerns that if the executive order is enacted, it would jeopardize their ability to fund the previously announced significant investment in the U.S. [3] - The executive order aims to lower prescription drug prices, causing global pharmaceutical companies to reassess their investment strategies in the U.S. [1][3] Group 2 - Pfizer executives have also voiced similar concerns regarding the uncertainty of U.S. policies affecting their investments [3] - Trump's administration has indicated that pharmaceutical companies may face tariffs if they do not lower drug prices, further complicating the investment landscape [3] - The complexity of drug pricing in the U.S. involves intermediaries, which contrasts with the direct negotiations seen in Europe, leading to higher drug prices in the U.S. [3][4] Group 3 - Other pharmaceutical companies, such as Novartis and AstraZeneca, are advocating for reforms to reduce the role of intermediaries and address the disparity in drug pricing between the U.S. and Europe [4] - Danish pharmaceutical companies are particularly concerned about the uncertainty created by Trump's order, as it could negatively impact their operations and the economy [4] - The executive order specifically targets high-cost drugs in the U.S., including GLP-1 weight loss medications, which are priced significantly higher than in other countries [4]
美国药品“降价令”震动全球制药业，威胁罗氏500亿美元投资